Despite the increased risk conferred by BRCA1 mutations to cancer onset, pre-clinical and clinical data have ascertained that BRCA1 impairment is commonly associated with chemosensitivity in cancer cells [13,16]. This evidence concerns the gene BRCA1 and cancer.